ClinicalTrials.gg

Program

dersimelagon

Also written as “MT-7117”, “Dersimelagon” and “MT-7117 low dose”.

Its studies are mostly in Protoporphyria, Erythropoietic · Scleroderma, Diffuse · Lymphoma, Follicular · Renal Insufficiency, led by Tanabe Pharma.

Furthest: phase 3, since May 20, 202013 company-led studies, 1 open or runningNext primary completion: Dec 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Tanabe Pharma131 open or runningphase 3since May 20, 2020Jul 6, 2016Dec 2027phase 3 · NCT05005975

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 6, 2016First study: phase 1 study in HealthyFirst studyNCT02834442 · 144 enrolled · United Kingdom
  2. Mar 18, 2018Phase 1 study in Healthy VolunteerNCT03503266 · 6 enrolled · United Kingdom
  3. Apr 23, 2018Phase 2 study in Protoporphyria, ErythropoieticNCT03520036 · 102 enrolled · United States
  4. Sep 18, 2018Phase 1 study in Healthy VolunteerNCT03688022 · 50 enrolled · Germany
  5. Oct 3, 2019Phase 1 study in Lymphoma, FollicularNCT04116476 · 23 enrolled · United States
  6. May 20, 2020Phase 3 study in EPPNCT04402489 · 184 enrolled · United States, Australia, Canada and more
  7. Jun 17, 2020Phase 2 study in Scleroderma, DiffuseNCT04440592 · 76 enrolled · United States, Belgium, Canada and more
  8. Nov 23, 2020Phase 1 study in Renal InsufficiencyNCT04656795 · 32 enrolled · Germany
  9. Mar 10, 2021Phase 1 study in Healthy SubjectsNCT04793295 · 112 enrolled · United States
  10. Jul 28, 2021Phase 3 study in EPPNCT05005975 · 286 enrolled · United States, Australia, Bulgaria and more
  11. Jan 6, 2022Phase 1 study in Healthy SubjectsNCT05241535 · 29 enrolled · United States
  12. Nov 17, 2023Phase 3 study in Protoporphyria, ErythropoieticNCT06144840 · 165 enrolled · United States, Australia, Bulgaria and more
  13. Apr 24, 2025Phase 1 study in Healthy SubjectsNCT06994286 · 40 enrolled · China

Ahead

  1. Dec 2027Primary completion: phase 3 study in EPPNCT05005975

TargetBeta

MC1R →read by rule
“An orally bioavailable selective, non-peptide melanocortin-1 receptor (MC1R; melanocyte-stimulating hormone receptor; MSHR; melanin-activating peptide receptor; melanotropin receptor) agonist, that can potentially be used to prevent phototoxicity”NCIt, by rule
“Melanocortin receptor 1 agonist”ChEMBL 37, by rule

Studies

All 13 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06994286Healthy Subjects · China1CompletedJul 21, 202540
NCT06144840Protoporphyria, Erythropoietic · United States, Australia, Bulgaria and more3CompletedApr 14, 2026165
NCT05241535Healthy Subjects · United States1CompletedFeb 23, 202229
NCT05005975EPP · United States, Australia, Bulgaria and more3Active, not recruitingDec 2027286
NCT04793295Healthy Subjects · United States1CompletedFeb 4, 2022112
NCT04656795Renal Insufficiency · Germany1CompletedDec 4, 202132
NCT04440592Scleroderma, Diffuse · United States, Belgium, Canada and more2CompletedJan 17, 202476
NCT04402489EPP · United States, Australia, Canada and more3CompletedDec 14, 2021184
NCT04116476Lymphoma, Follicular · United States1CompletedFeb 16, 202123
NCT03688022Healthy Volunteer · Germany1CompletedDec 22, 201850
NCT03520036Protoporphyria, Erythropoietic · United States2CompletedSep 28, 2019102
NCT03503266Healthy Volunteer · United Kingdom1CompletedMay 11, 20186
NCT02834442Healthy · United Kingdom1CompletedJun 2017144

How it is read

Names in the registry

  • “MT-7117”, 9 entries
  • “Dersimelagon”, 1 entry
  • “MT-7117 low dose”, 1 entry
  • “MT-7117 high dose”, 1 entry
  • “MT-7117 Low Dose”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.